New antibody drug targets Hard-to-Treat cancers in first human trial
NCT ID NCT06636435
First seen Nov 01, 2025 · Last updated Jun 14, 2026 · Updated 32 times
Summary
This early-stage study tests a new drug called CBA-1205 in people with advanced solid tumors (like liver cancer or melanoma) that have not responded to other treatments. The main goal is to check the drug's safety and find the best dose. About 66 participants will receive the drug, and researchers will monitor side effects and measure how the body processes the drug.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA (HCC) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Kanagawa Cancer Center
RECRUITINGYokohama, Kanagawa, 241-8515, Japan
-
National Cancer Center Hospital
RECRUITINGChūō, Tokyo, 104-0045, Japan
-
National Cancer Center Hospital East
RECRUITINGKashiwa, Chiba, 277-8577, Japan
-
Niigata University Medical and Dental Hospital
RECRUITINGNiigata, Niigata, 951-8520, Japan
-
University of Yamanashi Hospital
RECRUITINGChūō, Yamanashi, 409-3898, Japan
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.